<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings</h1>
    <p class="timestamp">Published: 2024-01-16 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), requests public comment on two draft reevaluations with initial recommendations to change the status of two drugs, liraglutide and pertuzumab, on the NIOSH List of Antineoplastics and Other Hazardous Drugs in Healthcare Settings (List). The reevaluations were developed based on the process described in the NIOSH Procedure...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Centers for Disease Control and Prevention</p>
    <p><strong>Document Number:</strong> 2024-00693</p>
    <p><strong>Publication Date:</strong> 2024-01-16</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/01/16/2024-00693/request-for-public-comment-on-niosh-initial-recommendations-to-change-the-status-of-liraglutide-and">https://www.federalregister.gov/documents/2024/01/16/2024-00693/request-for-public-comment-on-niosh-initial-recommendations-to-change-the-status-of-liraglutide-and</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-00693</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
